荣昌生物(9995.HK):三季度增长符合预期 创新管线持续推进

中信建投证券
09 Nov 2024

核心观点2024 三季度,公司核心产品销售持续放量,单季度收入4.67亿元,同比增长57.10%,符合预期。同时公司三季度归母净亏损3.04 亿元,环比缩窄1.44 亿元。公司核心产品泰它西普与维迪西妥单抗覆盖自免与肿瘤领域,两款产品的临床研发与商业化推进均在稳步推进状态。公司RC18、RC88 多项临床试验成果公布,适应症拓宽、管线丰富未来可期。公司海外业务也已启航,看好公司在管线不断丰富、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10